p16 (C20) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-p16 (C20) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | p16 (C20) |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human |
| Isotype | n/a |
| Format | unconjugated |
| Size | 0.2 mg |
| Concentration | n/a |
| Applications | Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: p16(C20) reacts with p16 of human origin by Western Blotting, Immunoprecipitation, and Immunohistochemistry. Western Blotting starting dilution: 1:200. The progression through the cell cycle is regulated by cyclins and their cognate Cdks by promoting cell cycle transitions (1,2,3). This orderly progression can be inhibited by a family of proteins known as CDK inhibitors (CDIs) that bind to cyclin/Cdk complexes and halt cell division (3). p21 (also designated WAF1/Cip1) is one has been shown to inhibit the activity of each member of the cyclin/Cdk family and over expression of this protein inhibits the proliferation of mammalian cells (5). The expression of p21 is inducible by a wide range of stress stimuli and its transcription |
| Immunogen | Immunogen: Synthetic peptide mapping to the carboxy terminus of human p16. Competition Studies: A blocking peptide is also available MBS443018 for use in competititon studies. Each vial containing 100 ug of peptide in 0.5ml PBS with 0.1% sodium azide and 100 ug BSA. |
| Other Names | [p16, partial; P16; cyclin-dependent kinase inhibitor 2A; CDK4 inhibitor p16-INK4; CDKN2A; alternative reading frame; cell cycle negative regulator beta; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); multiple tumor suppressor 1; cyclin-dependent kinase inhibitor 2A; P16], [CDKN2A; CDKN2A; ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A] |
| Gene, Accession # | [p16], Gene ID: 1029, NCBI: ABD72255.1, UniProt: Q208B5 |
| Catalog # | MBS440018 |
| Price | $240 |
| Order / More Info | p16 (C20) Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1.) Bihani T, Mason DX, Jackson TJ, Chen SC, Boettner B, Lin AW. 2004. Differential oncogenic Ras signaling and senescence in tumor cells. Cell Cycle 3(9):1201-7. 2.) Weebadda WK, Jackson TJ, Lin AW. 2005. Expression of p16(INK4A) variants in senescent human fibroblasts independent of protein phosphorylation. J Cell Biochem. Apr 15;94(6):1135-47.3.) Mason DX, Jackson TJ, Lin AW. Molecular signature of oncogenic ras-induced senescence. Oncogene. 2004 Dec 9;23(57):9238-46.4.) Bihani T, Chicas A, Lo CP, Lin AW. 2007. Dissecting the senescence-like program in tumor cells activated by Ras signaling. J Biol Chem. Jan 26;282(4):2666-75.5.) Achour M, Jacq X, Ronde P, Alhosin M, Charlot C, Chataigneau T, Jeanblanc M, Macaluso M, Giordano A, Hughes AD, Schini-Kerth VB, Bronner C. 2007. The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene. Oct 15.1. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75(4):805-816.2. Gartel AL, Serfas MS, Tyner AL. 1996. p21 - -negative regulator of the cell cycle. Proc Soc Exp Biol Med 213(2):138-149.3. Moller MB. 2000. p27 in cell cycle control and cancer. Leuk Lymphoma 39(1-2):19-27.4. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. 2000. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol 183(1):18-27.5. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366(6456):634.6. Gorospe M, Wang X, Holbrook NJ. 1999. Functional role of p21 during the cellular response to stress. Gene Expr 7(4-6):377-385.7. Slingerland J, Pagano M. 2000. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183(1):10-17.8. Toyoshima H, Hunter T. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78(1):67-74.9. Shapiro GI, Edwards CD, Rollins BJ. 2000. The physiology of p16(INK4A)-mediated G1 proliferative arrest. Cell Biochem Biophys 33(2):189-197.10. Liggett WH Jr, Sidransky D. 1998. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16(3):1197-1206. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies